Pembrolizumab With Anlotinib in Advanced Oral Mucosal Melanoma: A Retrospective Trial
Our study suggested that pembrolizumab with anlotinib in patients with advanced OMM showed potential efficacy and manageable adverse effects. Further studies are needed to confirm the efficacy of this combination strategy.
Authors
- Xinwei Yang (ORCID: https://orcid.org/0000-0003-0776-8269)
- Yunteng Wu
- Hao Song (ORCID: https://orcid.org/0000-0002-6383-0605)
- G. Ren
- Yusheng Lu
- Xuhui Ma
- Chaoji Shi (ORCID: https://orcid.org/0000-0002-9456-5656)
- Yun Bi
- Houyu Ju
- Jingzhou Hu
Institutions
- Weifang Medical University (CN)
- Shanghai Jiao Tong University (CN)
- National Clinical Research Center for Digestive Diseases (CN)
- Shanghai Ninth People's Hospital (CN)
Publication Details
- Journal
- Oral Diseases
- Published
- 2026-02-09
- DOI
- https://doi.org/10.1111/odi.70206
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Shanghai Municipal Health Commission